Acorda Therapeutics Inc said on Monday that a low-dose version of its multiple sclerosis drug Ampyra did not work in a clinical study, a potentially positive result that will hold generic competition at bay until 2027.
A post-marketing study of Ampyra failed to show an improvement in patients' walking speed when 5 mg of the drug was given twice a day. Had the 5 mg version worked, generic rivals could have entered the market in 2017 or 2018.
http://ir.acorda.com/phoenix.zhtml?c...941&highlight=
Bonus information for reading my thread -->
From March 2010 through March 2011, approximately 46,000 people with multiple sclerosis (MS) filled at least one prescription for AMPYRA. Among those patients, there were 82 confirmed reports of seizure. This rate is consistent with that seen in AMPYRA clinical trials.
http://ir.acorda.com/phoenix.zhtml?c...306&highlight=
A post-marketing study of Ampyra failed to show an improvement in patients' walking speed when 5 mg of the drug was given twice a day. Had the 5 mg version worked, generic rivals could have entered the market in 2017 or 2018.
http://ir.acorda.com/phoenix.zhtml?c...941&highlight=
Bonus information for reading my thread -->
From March 2010 through March 2011, approximately 46,000 people with multiple sclerosis (MS) filled at least one prescription for AMPYRA. Among those patients, there were 82 confirmed reports of seizure. This rate is consistent with that seen in AMPYRA clinical trials.
http://ir.acorda.com/phoenix.zhtml?c...306&highlight=
Comment